Literature DB >> 11898498

Choices in medical management for prevention of acute ischemic stroke.

J D Fleck1, J Biller.   

Abstract

Stroke is a leading cause of death and disability. Although advances are being made in the treatment of acute ischemic stroke, its prevention is equally as important. Identification and management of risk factors are essential. Medical therapy is also helpful in the secondary prevention of ischemic stroke. There are currently four platelet-antiaggregating agents used to prevent ischemic stroke: aspirin, aspirin plus dipyridamole, clopidogrel, and ticlopidine. The relevant studies proving their efficacy are noted, as are some of their similarities and differences. The use of warfarin is also discussed.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11898498     DOI: 10.1007/s11910-001-0075-x

Source DB:  PubMed          Journal:  Curr Neurol Neurosci Rep        ISSN: 1528-4042            Impact factor:   5.081


  44 in total

1.  Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients.

Authors:  S Yusuf; P Sleight; J Pogue; J Bosch; R Davies; G Dagenais
Journal:  N Engl J Med       Date:  2000-01-20       Impact factor: 91.245

Review 2.  Antithrombotic and thrombolytic therapy for ischemic stroke.

Authors:  G W Albers; J D Easton; R L Sacco; P Teal
Journal:  Chest       Date:  1998-11       Impact factor: 9.410

Review 3.  Aspirin as a therapeutic agent in cardiovascular disease. Special Writing Group.

Authors:  V Fuster; M L Dyken; P S Vokonas; C Hennekens
Journal:  Circulation       Date:  1993-02       Impact factor: 29.690

4.  Summary of the second report of the National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults (Adult Treatment Panel II)

Authors: 
Journal:  JAMA       Date:  1993-06-16       Impact factor: 56.272

5.  Association between high homocyst(e)ine and ischemic stroke due to large- and small-artery disease but not other etiologic subtypes of ischemic stroke.

Authors:  J W Eikelboom; G J Hankey; S S Anand; E Lofthouse; N Staples; R I Baker
Journal:  Stroke       Date:  2000-05       Impact factor: 7.914

6.  Prevention of stroke by antihypertensive drug treatment in older persons with isolated systolic hypertension. Final results of the Systolic Hypertension in the Elderly Program (SHEP). SHEP Cooperative Research Group.

Authors: 
Journal:  JAMA       Date:  1991-06-26       Impact factor: 56.272

7.  A randomised, blinded, trial of clopidogrel versus aspirin in patients at risk of ischaemic events (CAPRIE). CAPRIE Steering Committee.

Authors: 
Journal:  Lancet       Date:  1996-11-16       Impact factor: 79.321

8.  The effect of pravastatin on coronary events after myocardial infarction in patients with average cholesterol levels. Cholesterol and Recurrent Events Trial investigators.

Authors:  F M Sacks; M A Pfeffer; L A Moye; J L Rouleau; J D Rutherford; T G Cole; L Brown; J W Warnica; J M Arnold; C C Wun; B R Davis; E Braunwald
Journal:  N Engl J Med       Date:  1996-10-03       Impact factor: 91.245

9.  Influence of aspirin in the management of asymptomatic carotid artery stenosis. VA Cooperative Study Group on Asymptomatic Carotid Stenosis.

Authors:  R W Hobson; W C Krupski; D G Weiss
Journal:  J Vasc Surg       Date:  1993-02       Impact factor: 4.268

Review 10.  Hyperhomocysteinemia and atherosclerotic vascular disease: pathophysiology, screening, and treatment. off.

Authors:  J H Stein; P E McBride
Journal:  Arch Intern Med       Date:  1998-06-22
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.